An FDA-approved melanocortin receptor agonist, PT-141 works through the central nervous system to enhance sexual arousal. Unlike PDE5 inhibitors, it acts on brain pathways rather than vascular mechanisms.
An FDA-approved melanocortin receptor agonist, PT-141 works through the central nervous system to enhance sexual arousal. Unlike PDE5 inhibitors, it acts on brain pathways rather than vascular mechanisms.
GHK -Cu (Glycyl-L-Histidyl-L-Lysine-Copper) is a human-derived tripeptide with an extraordinary ability to bind to copper. Discovered in the 1960s by biochemist Loren Pickart, this peptide has proven to be a potent activator of skin regeneration, with solid evidence in preclinical in vitro and in vivo studies.
It stimulates the production of collagen types I and III, improving skin firmness and elasticity.
It reduces inflammatory markers such as IL-6 and TNF-α, protecting dermal tissue.
It promotes the proliferation of fibroblasts and keratinocytes to repair wounds faster.
It strengthens the lipid barrier and improves moisture retention in the dermis.
Copper acts as a cofactor of superoxide dismutase, neutralizing free radicals.
It activates genes for repairing and remodeling the extracellular matrix.